Brought to you by:
EACTS 2025 hears new data on aortic arch remodelling device
Data from the AMDS PERSEVERE and PROTECT trials—both assessing the use of the Ascyrus medical dissection stent (AMDS, Artivion)—were presented in late-breaking science presentations at the 39th European Association for Cardio-Thoracic Surgery (EACTS) annual meeting (8–11 October, Copenhagen, Denmark). The…
Artivion granted FDA humanitarian device exemption for the AMDS hybrid prosthesis
Artivion recently announced that the Food and Drug Administration (FDA) has granted a humanitarian device exemption (HDE) for use of the AMDS hybrid prosthesis (formerly known as the Ascyrus Medical dissection stent) in acute DeBakey type I dissections in the…
Enrollment begins in PERSEVERE clinical trial of hybrid prothesis for aortic dissection
Artivion announced today that it has initiated enrollment in the PERSEVERE clinical trial to determine if patients with an acute DeBakey Type I aortic dissection can be treated safely and effectively using the AMDS hybrid prosthesis. The trial is designed to…